Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2331519 | 1.00 | BTK (0.52) | BTKUSP30BRD4PIK3CDNSD2 | |
| SCHEMBL9911789 | 0.95 | NSD2 (0.53) | BTKUSP30BRD4NSD2ALDH1A1 | |
| SCHEMBL26911521 | 0.92 | GBA1 (0.46) | BTKUSP30NSD2CNR1CNR2 | |
| SCHEMBL9911806 | 0.91 | NSD2 (0.50) | BTKUSP30BRD4NSD2ALDH1A1 | |
| SCHEMBL16908187 | 0.87 | PIK3CD (0.49) | BTKUSP30BRD4PIK3CDNSD2 | |
| SCHEMBL22620999 | 0.87 | PIK3CD (0.49) | BTKUSP30BRD4PIK3CDNSD2 | |
| SCHEMBL23958291 | 0.85 | USP30 (0.56) | BTKUSP30BRD4PIK3CDALDH1A1 | |
| SCHEMBL2331315 | 0.85 | CHEK2 (0.47) | BTKNSD2MAPTMAPK1HTT | |
| SCHEMBL12390396 | 0.84 | CYP1A2 (0.60) | BTKUSP30BRD4PIK3CDALDH1A1 | |
| SCHEMBL30639820 | 0.84 | BTK (0.54) | BTKUSP30BRD4PIK3CDNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324226-B2 | Therapeutic oxy-phenyl-aryl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| EP-2227460-B1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER REC TECH LTD (GB) | 2012-06-20 | — | — | EP | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-08-18 | — | — | US | disclosed |
| EP-2227460-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053694-A1 | THERAPEUTIC OXY-PHENYL-ARYL COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201592-A1 | Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use | CHEK2, CHEK1, PLK1 | BTK 688/4885USP30 2421/4885BRD4 679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.